Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.47
+0.02 (0.16%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Generate Biomedicines Revenue
In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$31.89M
Revenue Growth
+55.89%
P/S Ratio
49.83
Revenue / Employee
$102,221
Employees
312
Market Cap
1.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGENB News
- 2 months ago - Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - Reuters
- 2 months ago - Drug developer Generate Biomedicines raises $400 million in US IPO - Reuters
- 2 months ago - Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - PRNewsWire
- 2 months ago - Generate Biomedicines aims to raise $425 million in US IPO - Reuters
- 2 months ago - Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView News
- 2 months ago - Generate Biomedicines IPO Registration Document (S-1) - SEC
- 2 months ago - Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO - Renaissance Capital